Why I keep coming back to direct response marketing
A client asked me recently whether direct response marketing was still worth doing, or whether it was a bit, well, last decade. Fair question. The phrase itself sounds like something out of a 1990s sales manual, and the examples people reach for first (cold calls, clipped coupons) don’t exactly help.
But the idea behind it is one of the most useful things in marketing, and I find myself recommending it constantly, especially to biotech and diagnostics teams who are trying to get something moving without a six-month campaign plan.
The idea is simpler than the name suggests
You design a campaign that asks the recipient to do one specific thing, now. Click here. Register by Friday. Reply to book a slot. That’s it. No brand-building detour, no nurturing sequence, just a clear ask with a clear deadline. That doesn’t mean it replaces a proper marketing plan, it just does a specific job within one.
You’ve seen it everywhere, even if you didn’t call it that. The webinar invite with a registration cut-off. The early-bird conference rate. The promo code that expires Sunday. The “only 20 demo slots available” email. All direct response.
Why it actually works
The reason is unglamorous: scarcity and time pressure make people decide. If something is available forever, your brain quietly files it under “later” and you never come back to it. If it closes Friday, you either act or you consciously let it go. Either is better, from a marketer’s perspective, than the indefinite maybe.
The other thing I like about it, and this is the part I find myself emphasising with CEOs whose teams are struggling to show impact, is that it’s measurable in a way most marketing isn’t. You sent X emails, Y people registered, Z showed up. You know what happened. You know what to change next time. That’s rarer than it should be.
What it looks like in life sciences
The biotech version of this looks different from the iPhone-half-price version. A social media contest is probably not going to land with clinical lab directors. But the underlying mechanic translates well:
A webinar with a real speaker and a registration deadline. A limited number of demo slots at a conference. An early-access window for a new assay. A case study sent to a defined account list with a follow-up call already on the calendar. None of these feel like “direct response marketing” in the traditional sense, but they all are. Specific ask, specific deadline, specific next step.
Where it usually goes wrong
The mistakes I see most often are the same ones across industries. Manufactured urgency that nobody believes (“limited time offer!” on something that’s been on the website for six months). A call to action that requires three clicks and a form to figure out. Sending the campaign to everyone on the list because segmenting felt like too much effort (and yes, that comes back to knowing your audience). Forgetting that the offer itself has to be worth acting on, no amount of clever copy fixes a weak proposition.
The other thing worth saying, particularly for European audiences: privacy matters. Not just because of GDPR, though that too. Because aggressive data practices cost you more in trust than they earn in conversions. People remember being spammed.
A useful place to start
If you’re a CEO looking at your marketing team and wondering why the pipeline feels thin between product launches, this is often the most useful place to start. It’s specific, it’s quick to set up, and you’ll know within a few weeks whether it worked. That’s a better starting point than another brand refresh.